Drug Profile

NMRA 861

Alternative Names: NMRA-861

Latest Information Update: 22 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vanderbilt University
Developer Neumora Therapeutics; Vanderbilt University
Class Antipsychotics; Neuropsychotherapeutics
Mechanism of Action Muscarinic M4 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Schizophrenia
Preclinical Neurological disorders; Psychotic disorders

Most Recent Events

09 Jul 2025 Neumora Therapeutics has a patent protection for NMRA 861
09 Jul 2025 Phase-I clinical trials in Schizophrenia (PO)
09 Jul 2025 Pharmacodynamics and adverse events data from preclinical studies in Neurological disorders, Psychiatric disorders and Schizophrenia released by Neumora Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com